ProCE Banner Activity

Metastatic Colorectal Cancer: Areas of Consensus and Controversy Among Experts

Clinical Thought
In this commentary on the treatment of metastatic colorectal cancer, I explore areas of consensus and controversy among experts including management of MSI-high/MMR-deficient tumors, treatment of transverse primaries, management of tumors with BRAF V600E mutations, and approaches in later lines of therapy.

Released: October 31, 2017

Expiration: October 30, 2018

No longer available for credit.

Share

Faculty

Tanios Bekaii-Saab

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Bayer Healthcare Pharma

Genentech TEXT Only

Lilly

Taiho Pharmaceuticals

Faculty Disclosure

Primary Author

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from Amgen, Merck, Exelexis, SillaJen, and Armo.